LYEL
LYEL
NASDAQ · Biotechnology

Lyell Immunopharma Inc

$11.01
+0.21 (+1.94%)
As of Sep 20, 10:26 PM ET ·
Financial Highlights (FY 2026)
Revenue
51.7K
Net Income
-395,296,328
Gross Margin
Profit Margin
-762,355.6%
Rev Growth
-92.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 29.6% 29.6%
Operating Margin -748,344.4% -673,510.3% -16.0% -15.0%
Profit Margin -762,355.6% -724,237.8% -14.9% -15.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 51.7K 687.5K 107.82M 110.08M
Gross Profit 31.94M 32.61M
Operating Income -386,901,558 -4,630,470,773 -17,264,565 -16,469,755
Net Income -395,296,328 -4,730,940,095 -16,079,673 -17,508,845
Gross Margin 29.6% 29.6%
Operating Margin -748,344.4% -673,510.3% -16.0% -15.0%
Profit Margin -762,355.6% -724,237.8% -14.9% -15.9%
Rev Growth -92.5% -92.5% +2.1% -2.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 170.75M 218.79M
Total Equity 336.15M 314.14M
D/E Ratio 0.51 0.70
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -371,410,446 -4,692,020,261 -19,078,562 -20,059,530
Free Cash Flow -8,704,547 -8,409,186